Q-omics provides the consensus-scored KIAA0930 profile across patient tissues and cancer cell-line models. KIAA0930 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KIAA0930 is differentially expressed in 18, with the highest sampling consensus in HNSC. Additionally, KIAA0930 protein abundance shows 20,376 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where KIAA0930 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA0930 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA0930 survival associations across molecular data types. KIAA0930 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA0930 RNA expression–survival associations across cancer types. High KIAA0930 expression shows unfavorable associations in LIHC, KIRC, MESO and ACC, but favorable associations in SCLC and UCEC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KIAA0930 RNA expression.
This table summarizes KIAA0930 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA0930. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA0930 shows higher tumor expression in HNSC, KIRC, KIRP, COAD, STAD and LIHC. The HNSC box plot shows higher KIAA0930 RNA expression in tumor versus normal tissue (log2 FC = +1.409, t-test p < 0.001).
This table shows molecular features associated with KIAA0930 in patient tissues and cancer cell lines. In patient samples, KIAA0930 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA0930 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
